ReviewProbiotics and antimicrobial proteins2026
Unveiling the Gastric Microbiome: Novel Insights into Early Detection and Pathogenesis of Gastric Cancer.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major global health burden and is frequently diagnosed at advanced stages owing to the limited sensitivity, invasiveness, and restricted availability of current screening strategies. Increasing evidence indicates that the gastric microbiome including Helicobacter pylori and diverse non-H. pylori bacteria, fungi, and viruses actively contribute to gastric carcinogenesis by modulating mucosal immunity, chronic inflammation, epithelial barrier integrity, and metabolism. High-throughput sequencing has revealed reproducible dysbiosis signatures in GC, characterized by enrichment of taxa such as Lactobacillus, Streptococcus, and Fusobacterium, and depletion of beneficial commensals, including Bifidobacterium and short-chain fatty acid producing anaerobes, some of which show promise as diagnostic or prognostic biomarkers. This review summarizes current knowledge on bacterial, fungal, and viral inhabitants of gastric tumors, highlighting their mechanistic roles in tumor initiation and progression and their potential as microbial indicators of disease. It further evaluates noninvasive and minimally invasive early detection strategies based on fecal and salivary microbiota profiling, urinary extracellular vesicles, and metabolomic fingerprints, alongside multi-omics integration and machine-learning models that combine microbial and host features to improve risk stratification. Finally, the review discusses therapeutic avenues including microbiota modulation, immunotherapy microbiome interactions, and personalized medicine frameworks that incorporate microbial signatures into clinical decision-making, underscoring the need for standardized, multicenter studies to translate gastric microbiome insights into robust tools for early detection and targeted intervention in GC.
Indexed as
Identifiers
42734869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.